An open-label study adding creatine monohydrate to ongoing medical regimens in patients with the fibromyalgia syndrome

Avi Leader, Daniella Amital, Alan Rubinow, Howard Amital*

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingConference contributionpeer-review

11 Scopus citations

Abstract

Fibromyalgia is an ill-defined condition that causes pain and disability but still lacks effective treatment. The aim of this open-label study was to assess the efficacy of administering a food supplement, creatine monohydrate, in an "add on" to existing therapies in patients with fibromyalgia. This study included 30 patients with fibromyalgia. After 8 weeks of receiving creatine, we witnessed a significant improvement in parameters reflecting severity of fibromyalgia, quality of life and sleep, disability, and pain. These results deteriorated 4 weeks after stopping creatine therapy. The findings of this study are preliminary and limited due to the small sample and relatively high rate of dropouts.

Original languageEnglish
Title of host publicationContemporary Challenges in Autoimmunity
PublisherBlackwell Publishing Inc.
Pages829-836
Number of pages8
ISBN (Print)9781573317627
DOIs
StatePublished - Sep 2009

Publication series

NameAnnals of the New York Academy of Sciences
Volume1173
ISSN (Print)0077-8923
ISSN (Electronic)1749-6632

Keywords

  • Anxiety
  • Depression
  • Fibromyalgia
  • Pain
  • Quality of life

Fingerprint

Dive into the research topics of 'An open-label study adding creatine monohydrate to ongoing medical regimens in patients with the fibromyalgia syndrome'. Together they form a unique fingerprint.

Cite this